Semaglutide Hair Loss: What Trials and New Studies Show

Semaglutide hair loss is uncommon in controlled trials but real. In the Wegovy weight-management trials, 3% of adults reported hair loss, compared with 1% on placebo (FDA, 2026). Newer observational studies link semaglutide and tirzepatide to higher odds of nonscarring hair loss. The best-supported explanation is telogen effluvium, a temporary shedding that stress such as rapid weight loss can trigger. A direct drug effect has been neither proven nor ruled out.

Key takeaways

• In three placebo-controlled Wegovy trials, 3% of adults on Wegovy reported hair loss, compared with 1% on placebo, which is far less often than nausea.
• Large 2025 to 2026 observational studies associate semaglutide and tirzepatide with higher odds of nonscarring hair loss, but they cannot prove the drugs cause it.
• Telogen effluvium is a temporary shedding that usually starts about 3 months after a stressor such as rapid weight loss, and it is the leading explanation.
• The trial figures come from FDA-approved Wegovy, while compounded semaglutide was not studied in those trials and is not FDA-approved.
• Patchy bald spots, scalp pain or scarring, or shedding that lasts beyond about 6 months are reasons to talk with a clinician.

Does semaglutide cause hair loss, or is it the weight loss?

The honest answer has layers. In randomized trials, hair loss was more common on semaglutide than on placebo, and newer observational studies show an association. The leading explanation is shedding triggered by weight-loss stress, but whether the drug contributes anything beyond the weight loss is still unknown.

Most online answers pick one of two positions. One says the drug clearly causes hair loss. The other says it is "just the weight loss." Each claims more than the evidence supports. Here is what each type of evidence adds:

• Randomized trials found more hair loss than placebo, but the absolute numbers were small (FDA, 2026).
• Observational cohorts found higher odds of nonscarring alopecia and telogen effluvium in people taking semaglutide or tirzepatide (Laryngoscope, 2026).
• Mechanism clues come from the same cohort. People with hair loss had lower follow-up BMI, which points toward weight-loss stress (Laryngoscope, 2026).
• The open question is whether semaglutide has any direct effect on hair. No study has settled it.

Searches for Ozempic hair loss and Wegovy hair loss are about the same active ingredient, semaglutide. The trial numbers below come from the Wegovy label. This article does not recommend supplements or hair products.

How common is semaglutide hair loss in the Wegovy trials?

Across three randomized, double-blind, placebo-controlled trials, 3% of adults on Wegovy reported hair loss, compared with 1% on placebo. That is a difference of about 2 percentage points (FDA, 2026).

The pooled trials included 2,116 adults on Wegovy and 1,261 on placebo, treated for up to 68 weeks. The adult population was 71% female, with a mean age of 48. That describes who was studied. It does not give separate rates for women and men. In a separate adolescent trial of 201 patients aged 12 and older, 4% on Wegovy reported hair loss, compared with 0% on placebo (FDA, 2026).

Digestive side effects in the same adult trials give a sense of scale:

Source: Wegovy prescribing information (FDA, 2026).

One point matters a lot here. These rates come from FDA-approved Wegovy. Compounded semaglutide was not studied in these trials and is not FDA-approved. For more on how the two differ, see branded vs compounded GLP-1 medications.

What is telogen effluvium, and why can weight loss trigger it?

Telogen effluvium (TE) is diffuse shedding that happens when a stressor pushes many growing hairs into the resting phase at once. It is a form of nonscarring alopecia, meaning the follicles are not destroyed (StatPearls, 2024).

Scalp hair cycles through phases. In a healthy scalp, about 85% of hairs are in the growing phase (anagen) and 15% are in the resting phase (telogen). Resting hairs eventually fall out. Under significant stress, a large share of growing hairs can shift into telogen together, and shedding rises (StatPearls, 2024).

Known triggers include:

• crash dieting
• low protein intake
• iron deficiency
• hypothyroidism (an underactive thyroid)
• severe illness
• major surgery

Several of these can overlap with fast weight loss and a reduced appetite.

Timing is where many people get confused. The triggering event usually happens about 3 months before shedding begins, with a range of 1 to 6 months. As a result, people often don't connect the two (StatPearls, 2024). Shedding that starts months into treatment fits this pattern.

By definition, acute TE lasts under 6 months and is self-limited. When a dietary or hormonal imbalance is involved, hair growth returns after it is corrected. A chronic form also exists (StatPearls, 2024). The weight-loss link gets support from the Laryngoscope cohort. GLP-1 users with hair loss had lower follow-up BMI than users without it, and the authors concluded that weight-loss-associated physiologic stress may contribute (Laryngoscope, 2026).

What the newer observational studies found

Large 2025 to 2026 studies link semaglutide and tirzepatide to higher odds of new nonscarring hair loss, especially TE. None of them can establish cause.

The Laryngoscope study followed adults with established care from 2018 to 2025. It used propensity matching, which pairs each GLP-1 user with a similar nonuser based on demographics, health conditions and medications linked to hair loss. Alopecia areata, an autoimmune cause of patchy loss, served as a negative control and was not associated with GLP-1 use (Laryngoscope, 2026). A negative control is an outcome the drug shouldn't affect. Finding no link there makes it less likely the main results are pure artifact.

The JAAD brief report by Herrera and Bordeaux included more than one million patients, according to a 2026 review in Dermatologic Surgery (Dermatologic Surgery, 2026).

The 2025 preprint reported an overall adjusted hazard ratio (HR) of 1.52. A hazard ratio compares how quickly an outcome occurs in two groups. The 95% confidence interval (CI), the range of plausible values, ran from 0.86 to 2.69. The authors called this result inconclusive. In women, the HR was 2.08 (95% CI 1.17 to 3.72). In men, it was 0.86 (95% CI 0.05 to 14.49), which is too imprecise to interpret (openRxiv preprint, 2025).

FAERS is the FDA's voluntary adverse-event reporting system. One analysis found 199 alopecia reports for semaglutide and 179 for tirzepatide. Semaglutide had a reporting odds ratio (ROR) of 2.46 (95% CI 2.14 to 2.83) (Acta Diabetologica, 2026).

What these studies can and can't prove

These studies show association, not causation. Even where the odds rise, the absolute risk increase appears small. A 2026 review describes the overall evidence as conflicting (Dermatologic Surgery, 2026).

• Diagnosis codes. Cohort studies rely on what clinicians recorded in health records. They do not rely on scalp exams done for research.
• Confounding. People starting GLP-1 medications often change their diets and lose weight quickly. Matching cannot adjust for factors that were never recorded, such as protein intake.
• Detection bias. People on a new medication see clinicians more often, so hair loss is more likely to be noticed and coded.
• Reporting bias. FAERS reports are shaped by media attention and reporting habits. They can flag a signal, but they cannot give rates.
• Odds versus absolute risk. One review reports absolute risk increases in alopecia under 0.35% for all GLP-1 receptor agonists studied (Dermatologic Surgery, 2026). Absolute risk is the actual change in how many people are affected. A doubling of odds can still mean a small absolute change.
• Peer review. The sex-stratified signal comes from a preprint that has not been peer reviewed.

Published estimates of hair loss range from about 3% to over 70%. A 2026 narrative review notes that hair loss prevalence was 3% to 7% in controlled trials but over 70% in some real-world cohorts (Acta Diabetologica, 2026). One cross-sectional study surveyed 254 GLP-1 users, and 76% self-reported hair loss (Dermatologic Surgery, 2026). Self-reported surveys of current users tend to attract people who noticed a problem, and they lack a placebo group. This is selection bias, and it may explain part of the gap.

The bottom line: weight-loss-driven TE fits the data best. Saying "it's just the weight loss" with full certainty still goes beyond what the evidence shows.

Is hair loss reported with tirzepatide too?

Yes, in observational data. One cohort found a stronger TE signal for tirzepatide than for other GLP-1 medications.

In the Laryngoscope cohort, tirzepatide was linked to higher TE odds at every follow-up. Compared with other GLP-1s, it also showed higher odds of TE, which semaglutide did not (Laryngoscope, 2026). The Dermatologic Surgery review describes another cohort of more than 360,000 people with a BMI of 30 or higher and no diabetes. In that cohort, the TE hazard ratio was higher for tirzepatide (HR 2.53) than for liraglutide (HR 1.56) (Dermatologic Surgery, 2026).

These are observational comparisons, so all the limits above apply. For broader differences between the two medications, see semaglutide vs tirzepatide pathway differences.

When to raise hair shedding with your clinician

Raise any shedding that worries you. It is a reasonable thing to report, and your clinician can weigh it alongside your intake, weight trend and other side effects. Some signs deserve prompt attention.

• Patchy or round bald spots. This pattern points away from TE and toward conditions such as alopecia areata. Case reports describe patchy loss of this kind after starting semaglutide (Acta Diabetologica, 2026). It may need a dermatology evaluation.
• Scalp pain, redness, scaling or scarring. TE does not scar the scalp (StatPearls, 2024).
• Shedding beyond about 6 months. Acute TE resolves within that window by definition.
• Thyroid-type symptoms or very low food intake. Examples include tiredness, cold sensitivity or constipation. Clinicians may consider testing for thyroid problems or iron deficiency when there is concern (StatPearls, 2024).

Questions worth bringing to your clinician:

1. Does my pattern fit telogen effluvium?
2. Could my pace of weight loss or my food intake be a factor?
3. Is any testing appropriate for me?
4. Should a dermatologist or my primary care clinician take a look?

Don't start supplements or change your medication on your own. New Blue does not offer hair-loss care, so evaluation may involve your primary care clinician or a dermatologist. For other side effects, see GLP-1 side effects week by week. This service is not for emergencies. Severe, persistent abdominal pain warrants urgent care.

How access works through New Blue

New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed.

1. You complete an asynchronous structured intake.
2. A licensed clinician reviews it. Some treatments or states may require a live visit. Not everyone qualifies. Eligibility depends on your intake and clinical review, and that's how it should work.
3. If prescribed, a licensed partner pharmacy ships the medication directly to you.

People with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2), or a history of pancreatitis, should not use these medications. A licensed clinician screens for this. The Wegovy label carries a boxed warning on MTC and MEN 2 and a warning on acute pancreatitis (FDA, 2026).

Compounded semaglutide is not FDA-approved. It has the same active ingredient as Ozempic and Wegovy, which are FDA-approved brand products. Compounded medications are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities. Read the compounding disclosure for details.

The semaglutide GLP-1 pathway ships to every state New Blue Health serves except North Dakota, and the tirzepatide GLP-1 pathway has the same North Dakota exclusion. Availability varies by state, so check state availability. This service is for adults 21 and older. New Blue is LegitScript certified. For current pricing, see the semaglutide treatment page.

Frequently Asked Questions

Is semaglutide hair loss permanent?

If the shedding is acute telogen effluvium, it is self-limited by definition. Hair growth returns once the trigger resolves or a deficiency is corrected (StatPearls, 2024). No one can promise a timeline for an individual. Shedding that lasts beyond about 6 months, or that comes with patchy spots or scalp changes, needs evaluation.

When does hair shedding usually start on semaglutide?

Telogen effluvium typically begins about 3 months after its trigger, with a range of 1 to 6 months (StatPearls, 2024). Because of that lag, shedding can appear well after treatment starts. In one survey of GLP-1 users, most self-reported hair loss began within 1 to 3 months of starting (Dermatologic Surgery, 2026).

Does faster weight loss or a higher dose make hair loss more likely?

Possibly, but this is not established. A 2026 review says available data suggest risk may rise with longer use, greater weight loss and higher doses, particularly with semaglutide and tirzepatide (Dermatologic Surgery, 2026). Any change to your treatment plan is a decision for you and your clinician.

Are women more likely to lose hair on semaglutide?

This is not established. A 2025 preprint that has not been peer reviewed found a signal in women (HR 2.08, 95% CI 1.17 to 3.72). The estimate for men was very imprecise (HR 0.86, 95% CI 0.05 to 14.49) (openRxiv preprint, 2025). Treat this as preliminary.

Does compounded semaglutide cause more or less hair loss than Wegovy?

No study compares them. The 3% versus 1% trial figures come from FDA-approved Wegovy. Compounded semaglutide has the same active ingredient as Ozempic and Wegovy, but it was not studied in those trials and is not FDA-approved.

Should I stop semaglutide if my hair is shedding?

Don't stop or change your medication on your own. Raise the shedding with your clinician, who can consider it alongside your weight trend, food intake and other side effects. Any decision about your treatment plan is made together with your clinician.

Sources

1. WEGOVY (semaglutide) injection / tablets: Highlights of Prescribing Information (Revised 02/2026). U.S. Food and Drug Administration (Novo Nordisk label), 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf
2. Nonscarring Alopecia in Adults Treated With GLP-1s: A Propensity Score Matched TriNetX Cohort Study. The Laryngoscope, 2026. https://pubmed.ncbi.nlm.nih.gov/42647098/
3. Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study. Journal of the American Academy of Dermatology, 2026. https://pubmed.ncbi.nlm.nih.gov/41707704/
4. The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms. Dermatologic Surgery, 2026. https://doi.org/10.1097/dss.0000000000005176
5. GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?. Acta Diabetologica, 2026. https://doi.org/10.1007/s00592-026-02812-3
6. Telogen Effluvium. StatPearls Publishing / NCBI Bookshelf (National Library of Medicine), 2024. https://pubmed.ncbi.nlm.nih.gov/28613598/
7. Risk of Hair Loss with Semaglutide for Weight Loss (preprint, not peer reviewed). openRxiv, 2025. https://doi.org/10.1101/2025.02.23.25322568

Medical disclaimer: This article is for educational purposes only and is not medical advice. Treatment decisions are made by a licensed clinician based on your individual intake and clinical review. New Blue Health is a technology and administrative services platform, not a medical provider.